EMMES to Coordinate NCI Anal Cancer Prevention Study
With the support of The EMMES Corporation, clinical investigators from the AIDS Malignancy Consortium (AMC) are preparing to enroll HIV-infected men and women throughout the United States and Puerto Rico in a major investigation of a prevention strategy for anal cancer. The study will enroll over 5,000 participants who are HIV-infected and who have pre-cancerous lesions. EMMES will provide operations, data management, site monitoring, and regulatory support under the eight-year, $89 million award. The study is scheduled to begin enrollment this month.